Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F
Istituto di Clinica Medica II-Università degli Studi di Bari, Italy.
Clin Exp Immunol. 1994 Jul;97(1):4-9. doi: 10.1111/j.1365-2249.1994.tb06571.x.
It is known that IFN therapy can induce the development of anti-IFN antibodies. In order to evaluate the biological and clinical significance of both neutralizing (NA) and non-neutralizing (binding) antibodies, 123 patients with chronic hepatitis C treated with recombinant IFN-alpha were examined. Among them, 15 were positive for NA and 24 for binding antibodies. The kinetics of NA appearance show that, in general, they develop early during the first 3 months of treatment. Moreover, NA seem to be clinically relevant, since they may be responsible for non-responsiveness to treatment in 53% of patients who develop them. The evaluation of the clinical significance of binding antibodies is more difficult. They appear significantly earlier in non-responders than in responders, but no differences were observed in the overall percentage of seroconversion between responders and non-responders. Thus, it is not possible at the moment to establish their possible role in inducing non-responsiveness.
已知干扰素（IFN）治疗可诱导抗IFN抗体的产生。为评估中和抗体（NA）和非中和抗体（结合抗体）的生物学及临床意义，对123例接受重组α-IFN治疗的慢性丙型肝炎患者进行了检测。其中，15例NA呈阳性，24例结合抗体呈阳性。NA出现的动力学表明，总体而言，它们在治疗的前3个月内早期出现。此外，NA似乎具有临床相关性，因为在出现NA的患者中，53%的患者对治疗无反应可能与之有关。评估结合抗体的临床意义更困难。它们在无反应者中出现的时间明显早于反应者，但在反应者和无反应者之间的血清转化总体百分比上未观察到差异。因此，目前尚无法确定它们在诱导无反应中可能发挥的作用。
